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3Précis
Endometrial ablation is not associated with elevated endometrial cancer or breast cancer risk
and most women treated with endometrial ablation do not need later hysterectomy in Finland.
4Abstract
Objective: To study the risk for endometrial cancer and breast cancer, and hysterectomy rate
after endometrial ablation in Finland.
Methods: In this retrospective cohort study, all women with endometrial ablation at ages 30-
49 in Finland (1997-2014) were extracted from the Hospital Discharge Register and linked to
Cancer Registry and Finnish Central Population Register. The primary outcome was cancer
incidences in the endometrial ablation cohort compared with those in the background
population of same age. Secondarily, postablation hysterectomy rate was compared with that
of a control cohort of similar-aged women extracted from the Finnish Central Population
Register. Multivariate regression models with adjustment for age, parity, number of cesarean
deliveries, history of sterilization, and the duration of follow-up were evaluated as risk factors
for postablation hysterectomy.
Results: In total, 154 cancers (the standardized incidence ratio [observed-to-expected ratio]
0.96, 95% confidence interval [CI] 0.82-1.13) were diagnosed among 5,484 women treated
with endometrial ablation during the follow-up of 39,892 women-years. The standardized
incidence ratio for endometrial cancer was 0.56 (95% CI 0.12-1.64), and for breast cancer
0.86 (95% CI 0.67-1.09). A total of 1,086 (19.8%) women had postablation hysterectomy.
Risk for hysterectomy was almost fourfold in the endometrial ablation cohort compared with
26,938 controls (adjusted hazard ratio [aHR]) 3.63, 95% CI 3.32-3.96). Factors predisposing
to postablation hysterectomy were leiomyomas (aHR 1.78, 95% CI 1.03-3.10), age under 35
years (aHR 1.44, 95% CI 1.15-1.81), at least two prior cesarean deliveries (aHR 1.27, 95% CI
1.04-1.55), and history of sterilization (aHR 1.15, 95% CI 1.01-1.32).
5Conclusion: Endometrial ablation was not associated with an elevated endometrial cancer or
breast cancer risk in Finland. Leiomyomas, young age, and history of prior cesarean
deliveries or sterilization were associated with an increased risk for postablation
hysterectomy.
6Introduction
Heavy menstrual bleeding is the most common form of abnormal uterine bleeding. It
decreases the quality of life of up to 25% of women (1) and causes a significant economic
burden due to substantial amount of outpatient visits and surgical interventions (1,2). Most
patients with heavy menstrual bleeding can be treated with medical therapy or endometrial
ablation without hysterectomy (3,4). During the last decades, new non-hysteroscopic
endometrial ablation techniques, safe and easy to perform in outpatient office setting, have
replaced the older hysteroscopic endometrial ablation methods (5,6).
The effect of endometrial ablation on later risk for cancer, endometrial cancer in particular, is
not well known (7,8) and population-based studies reporting solely the impact of the new
non-hysteroscopic endometrial ablations on endometrial cancer do not exist. In addition, it is
unknown if heavy menstrual bleeding is associated with increased risk for breast cancer.
Women using levonorgestrel-releasing intrauterine system for heavy menstrual bleeding have
decreased risk for endometrial cancer, but increased risk for breast cancer (9, 10).
Optimally, endometrial ablation relieves heavy menstrual bleeding permanently, but in some
cases later hysterectomy is needed (5,11). If the factors predisposing to hysterectomy could
be clarified, more individualized risk-benefit estimations could be made before treatment
decisions.
Thus, our primary aim of this nationwide study was to assess the risk for endometrial cancer
and breast cancer among women treated with endometrial ablation in Finland. Our secondary
aim was to identify risk factors for postablation hysterectomy.
7Materials and Methods
This study was approved by the Institutional Review Board of Hyvinkää Hospital. The
Finnish National Institute for Health and Welfare, after consulting the data protection
authority, approved the use of the confidential health register data in this research. Finnish
Central Population Register gave their permission to get the requested data on the cases and
to select the control women.
In this observational nationwide cohort study, we collected information on all women in
Finland who in 1997-2014 were between the ages of 30-49 years and had undergone
endometrial ablation according to the Hospital Discharge Register. Five control women of the
same age (+/- six months), living in the same area, and alive at the index date were randomly
selected for each endometrial ablation case from the Finnish Central Population Register to
assess the risk for later hysterectomy in the endometrial ablation treated women and in the
general population. The index date was the date of endometrial ablation of the case.
Endometrial ablation cases with cancer diagnosis before the beginning of the follow-up and
their controls, as well as other controls with a cancer diagnosis before the index date were
excluded.
All study data were obtained from administrative registers in Finland. The data linkages were
done using the unique personal identity code issued by the Finnish Population Register
Centre since 1967 to all citizens and permanent residents of Finland and used as the
identification key in all national registers.
Data on the endometrial ablations and other surgical procedures were obtained from the
registers of the National Institute for Health and Welfare. The information on surgical
8procedures since 1986 was obtained from the Hospital Discharge Register which has
summary information on patients discharged from public and private hospitals since 1969,
with almost 100% coverage (12), and the data accuracy and completeness have been reported
to be good (13). The codes of surgical procedures in this register are according to
NOMESCO Classification of Surgical Procedures since 1997. The code LCA 16 (destruction
of the endometrium) was used to extract the endometrial ablation patients from the register.
The data about sterilization procedures were obtained from the Sterilization Register, kept by
the National Institute for Health and Welfare. This register has information in electronic form
on all sterilizations performed in Finland since 1987.
The information on all liveborn deliveries was extracted from The Finnish Central Population
Register which has data on all live births in Finland in electronic form since 1969.
Information on the mode of deliveries was collected from the Medical Birth Register of the
National Institute of Health and Welfare which contains information on all deliveries of live
births and stillbirths with a gestational age of at least 22 weeks or birth weight of at least 500
g since 1987.
The data on cancer cases were extracted from the Finnish Cancer Registry, which receives
notifications of all cancer cases from hospitals and pathology laboratories, covering virtually
100% of diagnosed cancers in Finland since 1953 (14). Since 1961, reporting of new cancer
cases is mandatory by law in Finland. Cancer notifications submitted to the Finnish Cancer
Registry are stored in a database, and regular quality checks and cross-linkages with the data
of the Finnish Central Population Register and cause-of-death data of the Statistics Finland
are done to ensure the correctness of data.
9Our primary outcomes were all cancer diagnoses after endometrial ablation, especially
endometrial cancer and breast cancer. The expected number of cancers was calculated by
multiplying the number of women-years in each 5-year age group and calendar period by the
corresponding cancer incidence among all Finnish women for each primary cancer site. The
women-years at risk were calculated, starting from the date of endometrial ablation and
ending on December 31, 2014, or on emigration, or death, whichever occurred first. In
addition, censoring at the date of hysterectomy in the analyses for endometrial cancer risk
was done. We calculated standardized incidence ratios by dividing the number of observed
cancer cases by the expected cancer cases to assess the cancer risks among endometrial
ablation treated women. Ninety-five percent confidence intervals (CIs) for the standardized
incidence ratios were based on the assumption that the number of observed cases represents a
Poisson distribution (15).
The secondary outcome was hysterectomy after endometrial ablation. The independent
variables for the secondary outcome were the age at the endometrial ablation, parity, number
of prior cesarean deliveries, history of prior tubal sterilization, indication of endometrial
ablation, and the follow-up time from endometrial ablation. Adjusted hazard ratios (aHR)
with 95% CIs for hysterectomy were calculated with a multivariate Poisson regression model
using women-years as a model offset. The adjusted multivariate model included the
following variables: age at endometrial ablation, parity, number of cesarean deliveries,
sterilization, and the follow-up time. When comparing the risk for hysterectomy between
endometrial ablation cohort and controls (i.e. women without endometrial ablation), the
follow-up for the controls started from the index date of the corresponding endometrial
ablation case. When estimating the cumulative risk of hysterectomy, we defined death as a
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competing event that would prevent hysterectomy, and estimated cumulative incidence by
using a cause-specific hazard method proposed by Putter et al. (16).
Statistical significance was set at p<.05. Statistical analyses were conducted in statistical
program R (version 3.3.2) using popEpi package (version 0.4.1)
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Results
During the study period 1997-2014, a total of 5,591 women were treated with endometrial
ablation in Finland. After excluding women with history of cancer before the follow-up and
their controls (105 women in the endometrial ablation group and 494 matched controls),
women with prior cancer in the control group (n=485), and two women with discrepancies in
hysterectomy codes in the endometrial ablation group and their ten controls, the final study
cohort included 5,484 endometrial ablation treated women and 26,938 controls. The mean
age (± standard deviation, SD), at endometrial ablation was 42.4 ± 4.4 years (Table 1). The
median number of endometrial ablations performed yearly in Finland during the study period
was 329 (range 143-511). Over the study period, the number of endometrial ablations
increased; during 2010-2014 the growth was approximately 40%. Charasteristics of the study
cohorts are shown in Table 1. The mean follow-up time was 7.3 years (maximum 18 years).
In total, 154 new cancer cases were diagnosed among the endometrial ablation treated women
during 39,892 women-years at risk (Table 2). The standardized incidence ratio for all cancers
was 0.96 (95% confidence interval [CI] 0.82-1.13; 154 observed compared with 160 expected
cases). The standardized incidence ratio for all cancers in the first year of follow-up was 0.94
(95% CI 0.50-1.61), in one to five years 1.00 (95% CI 0.75-1.31), and after five years 0.94
(95% CI 0.76-1.16).
During the study period 1997-2014, the age-standardized incidence rate of endometrial
cancer in the Finnish population was 14.2/100,000 women-years, adjusted for age according
to the World Standard Population. After endometrial ablation, the standardized incidence
ratio for endometrial cancer was 0.56 (95% CI 0.12-1.64; three observed compared with five
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expected cases). Of the three endometrial cancer cases diagnosed after endometrial ablation,
two cases were diagnosed at early stage and one at unknown stage.
The standardized incidence ratio for breast cancer among endometrial ablation treated women
was 0.86 (95% CI 0.67-1.09; 67 observed compared with 78 expected cases). The
standardized incidence ratios for other cancers types were similarly not increased (data not
shown).
A total of 1,086 (19.8%) of women treated with endometrial ablation had hysterectomy
during the follow-up. Six women (0.1%) had a repeat endometrial ablation during the follow-
up. In the control cohort, 2,521 (9.4%) women had hysterectomy during the follow-up. The
mean age (± SD) at hysterectomy was 44.7 ± 5.2 years in endometrial ablation cohort, and
44.4 ± 5.7 years in the control cohort. The main indications for hysterectomy after
endometrial ablation were heavy menstrual bleeding (47.8%), leiomyomas (18.9%), other
unspecified indications (14.0%), dysmenorrhea (9.1%), and endometriosis or adenomyosis
(8.0%). In 20 cases (1.8%), the main indication for hysterectomy was endometrial
hyperplasia.
The aHR for hysterectomy in endometrial ablation treated women compared with controls
was 3.63 (95% CI 3.32-3.96, p<.001). Compared to the control cohort, the risk for
hysterectomy in the endometrial ablation cohort was highest during the first five years but at
ten years after endometrial ablation, the risk was still slightly increased (aHR 1.69, 95% CI
1.13-2.51) (Figure 1). Post-ablation hysterectomy risk was highest among women with a
prior history of leiomyoma diagnosis (aHR 1.78, 95% CI 1.03-3.10, p=.016), age younger
than 35 years at endometrial ablation (aHR 1.44, 95% CI 1.15-1.81, p=.002), or those with
two or more prior cesarean deliveries (aHR 1.27, 95% CI 1.04-1.55, p=.020) or with history
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of sterilization (aHR 1.15, 95% CI 1.01-1.32, p=.040) (Table 3). The median time from
endometrial ablation to hysterectomy was 4.9 years (range 0.0-18.0 years). The risk of
hysterectomy was highest during the first year after endometrial ablation (aHR 4.44, 95% CI
3.67-5.36, p<.001), and decreased during the follow-up (Table 3).
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Discussion
We found that endometrial ablation was not associated with an increased risk for endometrial
cancer or breast cancer in Finland. Later hysterectomy was needed only in 19.8% of cases.
Young age, leiomyomas, and history of cesarean deliveries or sterilization predicted
subsequent hysterectomy. Little is known about the impact of the new non-hysteroscopic
endometrial ablation techniques on later cancer risk. In our study, the risk for endometrial
cancer was not altered after endometrial ablation.
Only 0.05% of women treated with endometrial ablation were diagnosed with endometrial
cancer in our study. This is in line with a Scottish study which included also first-generation
endometrial ablations (7). Singh et al. (17) found no cases of endometrial cancer among
1,521 women with endometrial ablation with a median follow-up of 10 years but they did not
report whether the follow-up was censored at hysterectomy, after which risk for endometrial
cancer disappears. The risk for endometrial cancer among premenopausal women with
irregular uterine bleeding has been reported to be increased (18) but association with heavy
menstrual bleeding remains unknown. Our finding of postablation endometrial cancer risk
comparable to that of general population is based on a small number of cases but suggests
that no increased risk exists.
Our finding of no effect of endometrial ablation on breast cancer risk is in line with the only
previous study (7). In that study, 1.15% of the women with endometrial ablation had
subsequent diagnosis of breast cancer and this was 1.22% in our study. Treatment of heavy
menstrual bleeding with levonorgestrel-releasing intrauterine system was associated with an
increased risk for breast cancer (9,10) which could relate to altered intrinsic hormonal factors
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(i.e., hyperestrogenism, chronic anovulation). Our findings, however, imply that heavy
menstrual bleeding per se is not a risk factor for breast cancer.
Post-ablation hysterectomy rate of 19.8% is comparable to previous studies with women of
similar age and follow-up (13-20%) (7,8,19,20). The need for postablation hysterectomy
usually emerges in the first years (7,20) which was also noticed in our study; 75% of
hysterectomies were performed during four years after endometrial ablation. The risk for
hysterectomy was almost four times higher compared with other women of the same age. In
several studies, young age at endometrial ablation is a significant risk factor for hysterectomy
(19-22). Leiomyomas were a significant risk factor for hysterectomy in our study as well as
in a large study from England (22) and in a smaller US study (23). We also found that women
with postablation hysterectomy were more likely to have prior cesarean deliveries, a finding
already reported (20,23). In our study, majority of women with endometrial ablation were
sterilized, which reflects the contraception policy; in Finland sterilization is strongly
recommended before endometrial ablation.
The strengths of this study are large cohort size, long follow-up time, and population-based
data from national administrative and health registers with high level of coverage enabling
this type of research (24). We had virtually complete data on all endometrial ablations and
other gynecological operations, cancer diagnoses, and the deaths during the follow-up
minimizing the risk of selection bias. Also, our study represents solely the effects of the new
endometrial ablation techniques which are exclusively used currently with no difference in
efficacy compared with the first generation endometrial ablations (6,25). A limitation was the
lack of data on the specific endometrial ablation devices used but differences in effectiveness
between various non-hysteroscopic endometrial ablation devices do not exist (25). In Finland,
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data on the ethnic background cannot be recorded in the register studies according to current
data protection legislation. However, almost all Finns are Caucasians. Hence we can
conclude that the results of our study are generalizable to the Caucasian population of the
developed countries.
This study supports the role of endometrial ablation as an effective alternative to
hysterectomy in selected women with heavy menstrual bleeding. In most cases a subsequent
hysterectomy can be avoided, although there are factors that predict increased postablation
hysterectomy risk. Most importantly, endometrial cancer or breast cancer risk seems to be
unaffected by endometrial ablation which is reassuring when choosing treatment alternatives
for heavy menstrual bleeding.
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Table 1. Baseline characteristics of all Finnish women treated with endometrial ablation in 1997-2014
at ages 30-49 years and their control group at the beginning of the follow-up.
Patient charasteristic Endometrial ablation Controls p*
Number of women 5,484 26,938
Age at the beginning of follow-up (y)
30-34 329 (6.0%) 1,624 (6.0%) .955
35-39 1,286 (23.5%) 6,364 (23.6%) .789
40-44 2,152 (39.2%) 10,569 (39.2%) 1.000
45-49 1,718 (31.3%) 8,381 (31.1%) .772
Parity
0 282 (5.1%) 4,370 (16.2%) <.0001
1 575 (10.5%) 4,373 (16.2%) <.0001
2 2,082 (38.0%) 9,951 (36.9%) .160
3 1,629 (29.7%) 5,557 (20.6%) <.0001
≥4 917 (16.7%) 2,687 (10.0%) <.0001
History of tubal sterilization, n (%) 3,698 (67.4%) 5,114 (19.0%) <.0001
Indication of endometrial ablation
Heavy menstrual bleeding 4,488 (81.8%) NA NA
Leiomyomas 44 (0.8%) NA NA
Endometriosis/Adenomyosis 23 (0.4%) NA NA
Endometrial hyperplasia 23 (0.4%) NA NA
Other abnormal uterine bleeding 42 (0.8%) NA NA
Dysmenorrhea 30 (0.5%) NA NA
Other 834 (15.2%)  NA NA
* Chi-square test for equal proportions
NA, not appicable
NA, not applicable
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Table 2.  Cohort of Finnish Women Treated with Endometrial
Ablation at Ages 30 to 49: Follow-up 1997-2014.
Age n Women-Years Cancer Diagnoses
30-34 329 558 0
35-39 1,286 3,389 2
40-44 2,151 9,408 27
45-49 1,718 13,613 53
50-54 0 9,086 42
> 55 0 3,839 30
total 5,484 39,892 154
Number of all women classified according to the age at
endometrial ablation, women-years classified according to age at
follow-up, and cancers classified according to age at diagnosis.
Follow-up started from the date of endometrial ablation and
ended on 31 December 2014, or on emigration, or death,
whichever occurred first.
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Table 3. Poisson Multivariable Regression Model Analysis of Predictors for hysterectomy after endometrial
ablation.
Variable Number of
Hysterectomies
HR (95% CI) p aHR
(95% CI)*
p
Age at index date (y)
30-34 92 1.46 (1.17-1.83) .001 1.44 (1.15-1.81) .002
35-39 292 1.16 (1.00-1.34) .055 1.15 (0.99-1.34) .069
40-44† 416 1 1
45-49 286 0.91 (0.78-1.05) .196 0.90 (0.77-1.05) .171
Number of deliveries before index date
0† 56 1 1
1 122 1.13 (0.82-1.55) .459 1.06 (0.77-1.46) .729
2 387 0.89 (0.67-1.17) .398 0.82 (0.62-1.10) .186
≥3 521 1.02 (0.78-1.35) .873 0.91 (0.68-1.20) .495
Number of cesarean delivieres before index date
0† 838 1 1
1 135 1.23 (1.02-1.47) 0,028 1.09 (0.91-1.32) .336
≥2 113 1.44 (1.18-1.75) <.001 1.27 (1.04-1.55) .020
History of tubal sterilization before index date
no† 312 1 1
yes 774 1.17 (1.02-1.33) .023 1.15 (1.01-1.32) .040
Indication of endometrial ablation
Heavy menstrual bleeding† 873 1 1
Leiomyomas 13 1.76 (1.02-3.05) .042 1.78 (1.03-3.10) .041
Endometriosis/Adenomyosis 6 1.47 (0.66-3.27) .350 1.44 (0.64-3.24) .380
Endometrial hyperplasia 7 1.02 (0.49-2.15) .959 1.35 (0.64-2.85) .428
Other abnormal uterine bleeding 6 0.63 (0.28-1.40) .254 0.66 (0.30-1.47) .311
Dysmenorrhea 6 1.07 (0.48-2.38) .872 1.06 (0.47-2.37) .888
Other 175 0.76 (0.65-0.89) .001 0.83 (0.71-0.98) .029
Follow-up time, years since index date
0-0.99 351 4.47 (3.70-5.40) <.001 4.44 (3.67-5.36) <.001
1-4.99 535 2.44 (2.04-2.92) <.001 2.43 (2.03-2.91) <.001
5-9.99† 154 1 1
10-14.99 37 0.69 (0.48-0.99) .042 0.68 (0.48-0.98) .038
≥15 9 1.17 (0.60-2.29) .647 1.14 (0.58-2.23) .702
HR, hazard ratio; CI, confidence interval; aHR, adjusted hazard ratio
Index date, the date of endometrial ablation and the beginning of the follow-up.
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* Adjusted for age at endometrial ablation, parity, number of cesarean deliveries, sterilization, and follow-
up time.
† Reference level
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Figure 1. Cumulative Risk for Hysterectomy after Endometrial Ablation in Finland. Follow-
up 1997-2014.
